ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Running, not enrolling · Phase 2

Conditions studied: Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer

In brief

Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

Key facts

Study ID

NCT05318027

Run by

Abramson Cancer Center at Penn Medicine

People needed

70

Starts

2023-05-22

Expected to finish

2026-12-01

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (age >18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
• Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
• Ability read and respond in English
• Ability to provide informed consent to participate in the study

You may not qualify if…

• Patients who are bed bound at baseline (ECOG 4)
• Patients who rely on a wheelchair for ambulation

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.